Company profile: Vitro Biopharma

1.1 - Company Overview

Vitro Biopharma

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of stem cell therapy, cell lines, and cell culture media, including AlloRx Stem Cell therapy from Wharton’s jelly–derived MSCs for autoimmune and inflammatory disorders; MSC-Gro specialty media for MSC growth and expansion; research-grade cancer-associated and native fibroblasts; human umbilical cord and placenta-derived MSC lines; and MSC-Gro formulations (low serum, serum-free, CAF-specific).

Products and services

Cell Lines: High-quality Human Umbilical Cord Derived MSCs, Human Placenta Derived MSCs, and various Cancer-Associated Fibroblasts for in-vitro research applications across mesenchymal stem cell and CAF studies
AlloRx Stem Cell therapy: A cell-based therapy product derived from culture-expanded MSCs sourced from the Wharton’s jelly of umbilical cords, intended for autoimmune diseases and inflammatory disorders
MSC-Gro: A proprietary culture media developed for the growth and expansion of MSCs from umbilical cords, enhancing therapeutic benefits and cell yield

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Vitro Biopharma

AltPep

HQ: United States Website

Description: Provider of diagnostic and therapeutic solutions for amyloid diseases, including SOBA Diagnostics for early detection and SOBIN Therapeutics for early treatment by targeting toxic soluble oligomers; offerings also include anti-biofilm applications.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full AltPep company profile →

Alto Neuroscience

HQ: United States Website

Description: Provider of an AI-driven biomarker platform that integrates patients’ brain activity and behavior to identify likely responders and enable precision medicines, plus a clinical-stage pipeline for neuropsychiatric conditions, including ALTO-100 (BDNF) for MDD/PTSD, ALTO-300 for MDD, ALTO-202 (NMDA NR2B) for MDD/PTSD, and ALTO-101 (PDE4) for schizophrenia and other neuropsychiatric conditions.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Alto Neuroscience company profile →

Cerevance

HQ: United States Website

Description: Provider of therapeutics for CNS disorders, leveraging its NETSseq platform to identify novel targets. Pipeline includes CVN424, a first-in-class compound targeting a novel receptor with phase 2 efficacy in Parkinson’s disease; CVN766, a selective orexin 1 antagonist for psychiatric conditions focused on avoiding somnolence; and CVN293, a KCNK13 inhibitor under investigation for ALS and Alzheimer’s.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Cerevance company profile →

Minerva Neurosciences

HQ: United States Website

Description: Provider of clinical-stage biopharmaceutical product candidates for central nervous system diseases, including roluperidone (MIN-101) for negative symptoms of schizophrenia targeting serotonin, sigma, and alpha-adrenergic receptors, and MIN-301, a recombinant neuregulin-1β1 in preclinical development for Parkinson’s disease aimed at restoring brain tissue damage and improving motor function.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Minerva Neurosciences company profile →

Accelerated Care Plus

HQ: United States Website

Description: Provider of rehabilitation and dysphagia treatment technologies and services, including OmniVR virtual reality therapy with 3D motion capture; OmniVersa multi-modality electrotherapy and ultrasound for pain management; Synchrony Dysphagia Solutions using surface electromyography and patterned electrical stimulation; ACPlus cloud platform for skilled nursing facilities with EHR integration and analytics; clinical services and ACP University continuing education.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Accelerated Care Plus company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Vitro Biopharma

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Vitro Biopharma

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Vitro Biopharma's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Vitro Biopharma's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Vitro Biopharma

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Vitro Biopharma's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Vitro Biopharma's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Vitro Biopharma

4.2 - Public trading comparable groups for Vitro Biopharma

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Vitro Biopharma

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Vitro Biopharma

What does Vitro Biopharma do?

Vitro Biopharma is a provider of stem cell therapy, cell lines, and cell culture media, including AlloRx Stem Cell therapy from Wharton’s jelly–derived MSCs for autoimmune and inflammatory disorders; MSC-Gro specialty media for MSC growth and expansion; research-grade cancer-associated and native fibroblasts; human umbilical cord and placenta-derived MSC lines; and MSC-Gro formulations (low serum, serum-free, CAF-specific).

Who are Vitro Biopharma's competitors?

Vitro Biopharma's competitors and similar companies include AltPep, Alto Neuroscience, Cerevance, Minerva Neurosciences, and Accelerated Care Plus.

Where is Vitro Biopharma headquartered?

Vitro Biopharma is headquartered in United States.

How many employees does Vitro Biopharma have?

Vitro Biopharma has 1,000 employees 🔒.

When was Vitro Biopharma founded?

Vitro Biopharma was founded in 2010 🔒.

What sector and industry vertical is Vitro Biopharma in?

Vitro Biopharma is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Vitro Biopharma

Who are the top strategic acquirers in Vitro Biopharma's sector and industry

Top strategic M&A buyers and acquirers in Vitro Biopharma's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Vitro Biopharma?

Top strategic M&A buyers groups and sectors for Vitro Biopharma include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Vitro Biopharma's sector and industry vertical

Which are the top PE firms investing in Vitro Biopharma's sector and industry vertical?

Top PE firms investing in Vitro Biopharma's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Vitro Biopharma's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Vitro Biopharma's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Vitro Biopharma's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Vitro Biopharma include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Vitro Biopharma's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Vitro Biopharma?

The key public trading comparables and valuation benchmarks for Vitro Biopharma include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Vitro Biopharma for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Vitro Biopharma with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Vitro Biopharma's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Vitro Biopharma with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Vitro Biopharma's' sector and industry vertical?

Access recent funding rounds and capital raises in Vitro Biopharma's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Vitro Biopharma

Start Free Trial Book a Demo